



## Curriculum Vitae

Personal information **Nikica Mirošević Skvrce**

### Work experience

---

1. Employer: Agency for Medicinal Products and Medicinal Devices (HALMED)
  - Start date: 012005
  - End date:
  - Position: Principal Advisor for pharmacovigilance and rational pharmacotherapy; Chair of Safety Committee
  - Activities: Pharmacovigilance, Rational Pharmacotherapy, Clinical assessment of documentation, Assessment of RMP, PSUR, teaching in Pharmacovigilance, Pharmacogenetics and Drug interactions, Medication errors
  - Country: Croatia

### Education and training

---

1. Subject: European Programme in Pharmacovigilance and Pharmacoepidemiology, Master
  - Start date: 092012
  - End date: 122014
  - Qualification: Master
  - Organisation: The title of the research: Effectiveness of risk minimisation measures for (es)citalopram
  - Country:
2. Subject: Doctoral Study in Biomedicine and Health Sciences (PhD program), School of Medicine, University of Zagreb
  - Start date: 102007
  - End date: 062014
  - Qualification: PhD
  - Organisation: The title of the the research: Pharmacogenetic predisposition for developing ADRs caused by statins
  - Country: Croatia
3. Subject: Faculty of Pharmacy and Biochemistry, University of Zagreb
  - Start date: 091998
  - End date: 022004
  - Qualification: BPharm
  - Organisation:
  - Country: Croatia

### Additional information

---

#### Publications

1. Mirosevic Skvrce N, Galic I, Pacadi C, Kandzija N, Mucalo I. Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation. *Res Social Adm Pharm.* 2019 Oct 7 2. Ganoci L, Božina T, Mirošević Skvrce N, Lovrić M, Mas P, Božina N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. *Drug Metab Pers Ther.* 2017;32(1):11\_21. 3. Mirošević Skvrce N, Macolić Šarinić V, Šimić I, Ganoci L, Muičević Katanec D, Božina N. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case\_control study. *Pharmacogenomics.* 2015;16(8):803\_15. 4. Mirošević Skvrce N, Božina N, Zibar L, Barišić I, Pejnović L, Macolić Šarinić V. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. *Pharmacogenomics.* 2013;14(12):1419\_1431. 5. Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D, Bozina N, Tomic S. Adverse drug reactions caused by drug\_drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. *Croat Med J.* 2011;52(5):604\_14.

#### Projects

SCOPE ADVANCE ACCESS

#### Memberships

International Society of Pharmacovigilance (ISOP) The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP)

#### Other Relevant Information